Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of TSU-68 plus S-1 and oxaliplatin in metastatic colorectal cancer
jRCT2080221366Phase 2
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of orantinib in metastatic colon cancer (mCRC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
orantinib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on jRCT2080221366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221366.